Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 81

Sort by

Sort Order Select

Journal Articles

Disparities in CAR-T Therapy Access and Outcomes: Variation in Referral Patterns for CAR-T Therapy in Patients with Newly Diagnosed Malignancies at an Academic Center in North Carolina

Blood (2024) 144 (Supplement 1): 5044.

https://doi.org/10.1182/blood-2024-211637

Published: 2024

Journal Articles

The Impact of Multiple Myeloma on Care Partner Well-Being, Work Productivity, and Resource Use in the United States and Western Europe

Kathy Annunziata, Nikoletta Sternbach, Hitomi Tanaka, Marco DiBonaventura, Joseph C. Cappelleri, Jack Watkins, David Hughes, Aster Meche, Chai Hyun Kim, C. Todd Kennedy, Hans Scheurer, Thomas W. LeBlanc

Blood (2024) 144 (Supplement 1): 3762.

https://doi.org/10.1182/blood-2024-201802

Published: 2024

Journal Articles

Updated Results of a Matching-Adjusted Indirect Comparison of Elranatamab Versus Teclistamab in Patients with Triple-Class Exposed/Refractory Multiple Myeloma

Isha Mol, Yannan Hu, Thomas W. LeBlanc, Joseph C. Cappelleri, Haitao Chu, Guido Nador, Didem Aydin, Isabel Perez-Cruz, Patrick Hlavacek

Blood (2024) 144 (Supplement 1): 3367.

https://doi.org/10.1182/blood-2024-206951

Published: 2024

Journal Articles

An Indirect Comparison of Elranatamab's Progression-Free Survival, Duration of Response, and Overall Survival from MagnetisMM-3 Versus Real-World External Control Arms in Triple-Class Refractory Multiple Myeloma

Luciano J. Costa, Thomas W. LeBlanc, Hans Tesch, Pieter Sonneveld, Sarasa M.A. Johnson, Francis Vekeman, Patrick Hlavacek, Aster Meche, Paul Cislo, David Hughes, Guido Nador, Marco DiBonaventura

Blood (2024) 144 (Supplement 1): 2401.

https://doi.org/10.1182/blood-2024-203920

Published: 2024

Journal Articles

Pre-Transplant Patient-Reported Outcomes Are Associated with Health Care Utilization and Transplant-Related Complications at One-Year Post-Transplant

Anna Barata, Richard Newcomb, Patrick Connor Johnson, Ella Caruso, Porsha Lark, Emelia J. Farnam, Thomas W. LeBlanc, Stephanie J. Lee, Areej El-Jawahri

Blood (2024) 144 (Supplement 1): 2330.

https://doi.org/10.1182/blood-2024-202065

Published: 2024

Journal Articles

Multi-Site Randomized Trial of a Collaborative Palliative and Oncology Care Model for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Receiving Non-Intensive Therapy

Areej El-Jawahri, Alison R Kavanaugh, Joseph A Greer, Vicki Jackson, Jillian Gustin, Alice Mims, Albert Cook, Thomas W. LeBlanc, Amir T. Fathi, Gabriela S. Hobbs, Andrew M. Brunner, Jennifer S Temel

Blood (2024) 144 (Supplement 1): 117.

https://doi.org/10.1182/blood-2024-209628

Published: 2024

Journal Articles

Treatment Experience of Patients with Acute Myeloid Leukemia in the Era of Novel Therapies: A Longitudinal Electronic Patient-Reported Outcomes Study

Mihir N. Patel, Allison O. Taylor, Brenda Branchaud, David Campbell, Anneli N. Kramer, Kris W. Herring, Jesse D. Troy, Thomas W. LeBlanc

Blood (2024) 144 (Supplement 1): 2422.

https://doi.org/10.1182/blood-2024-193842

Published: 2024

Journal Articles

Perceptions of Treatment Tolerability and Its Relationship to Income in Patients with Hematologic Malignancy: Findings from the Cancer Experience Registry

Erica E Fortune, Sabrina Pink, Kara Doughtie, Claire Saxton, Thomas W. LeBlanc, Joanne Buzaglo, Aude Roborel de Climens, France Ginchereau Sowell, Anubha Shukla, Melissa F Miller

Blood (2024) 144 (Supplement 1): 2437.

https://doi.org/10.1182/blood-2024-210340

Published: 2024

Journal Articles

Factors Associated with Early Quality of Life Response to Palliative Care during Hematopoietic Cell Transplantation

Richard Newcomb, Hermioni L Amonoo, Alison R Kavanaugh, James Fausto, Jason A Webb, Joseph A Greer, Jennifer S Temel, Porsha Lark, Dustin J Rabideau, Thomas W. LeBlanc, Stephanie J. Lee, Areej El-Jawahri

Blood (2024) 144 (Supplement 1): 5056.

https://doi.org/10.1182/blood-2024-207178

Published: 2024

Journal Articles

Experienced or Perceived Burdens and Associated Quality of Life Impacts of Anemia and Transfusion Dependence in Myelofibrosis: A Patient Self-Report Survey Analysis

Thomas W. LeBlanc, Hannah Collacott, Valentín García Gutiérrez, Sr., Ned Weinshenker, Ruth Fein Revell, Alicia O'Neill, Anna P Cardellino, Shiyuan Zhang, Dwaipayan Patnaik, Melissa Ross

Blood (2024) 144 (Supplement 1): 3815.

https://doi.org/10.1182/blood-2024-206086

Published: 2024

Journal Articles

Updated Results of a Matching-Adjusted Indirect Comparison of Elranatamab Versus Physician's Choice of Treatment in Patients with Triple-Class Exposed/Refractory Multiple Myeloma

Isha Mol, Yannan Hu, Thomas W. LeBlanc, Joseph C. Cappelleri, Haitao Chu, Guido Nador, Didem Aydin, Isabel Perez-Cruz, Patrick Hlavacek

Blood (2024) 144 (Supplement 1): 7028.

https://doi.org/10.1182/blood-2024-206856

Published: 2024

Journal Articles

Outcomes By Frailty in IC-Ineligible Newly Diagnosed AML - a Real-World Evidence Comparison By Treatment with Hypomethylating Agents + Ivosidenib or Venetoclax

B. Douglas Smith, Curtis A. Lachowiez, Alexander J. Ambinder, Gary Binder, Anne Angiolillo, Ravi Potluri, Eros Papademetriou, Thomas W. LeBlanc

Blood (2024) 144 (Supplement 1): 2855.

https://doi.org/10.1182/blood-2024-210603

Published: 2024

Journal Articles

Understanding Sociodemographic Barriers in Hematopoietic Stem Cell Transplantation Among Patients with Hematologic Malignancies: Insights from a North Carolina Cohort

Marie Michele Sainvil, Melissa Lowe, Delaney Underwood, Yan Li, Tomi F. Akinyemiju, Taewoong Choi, Cristina Gasparetto, Mitchell Horwitz, Gwynn D. Long, Richard Lopez, Stefanie Sarantopoulos, Edwin Alyea, III, Nelson J. Chao, Thomas W. LeBlanc, Yubin Kang, Sendhilnathan Ramalingam, Anthony D. Sung, Sanghee Hong

Blood (2024) 144 (Supplement 1): 2295.

https://doi.org/10.1182/blood-2024-211219

Published: 2024

Journal Articles

A Comparison of Acute Myeloid Leukemia (AML) Regimens: Hypomethylating Agents Combined with Ivosidenib or Venetoclax in Newly Diagnosed Patients with IDH1 Mutations: A Real-World Evidence Study

B. Douglas Smith, Curtis A Lachowiez, Alexander Joseph Ambinder, Gary Binder, Anne Angiolillo, Assaf Vestin, Robert Paglia, Ravi Potluri, Eros Papademetriou, Thomas W LeBlanc

Blood (2023) 142 (Supplement 1): 971.

https://doi.org/10.1182/blood-2023-173033

Published: 2023

Journal Articles

Multi-Site Randomized Trial of Inpatient Palliative Care for Hospitalized Patients Undergoing Hematopoietic Stem Cell Transplantation

Areej El-Jawahri, Thomas W LeBlanc, Alison Kavanaugh, Jason Webb, James Fausto, Lara Traeger, Joseph Greer, Vicki Jackson, Nora Horick, Zachariah Defilipp, Yi-Bin Chen, Stephanie J. Lee, Jennifer Temel

Blood (2023) 142 (Supplement 1): 913.

https://doi.org/10.1182/blood-2023-185735

Published: 2023

Journal Articles

A Positive Psychology Intervention in Allogeneic Hematopoietic Stem Cell Transplantation Survivors (PATH) to Promote Well-Being: Randomized Controlled Feasibility and Preliminary Efficacy Trial

Hermioni L Amonoo, Michelle Guo, Elizabeth Daskalakis, Emma Deary, Stephanie J. Lee, Thomas W LeBlanc, Jeff C. Huffman, Areej El-Jawahri

Blood (2023) 142 (Supplement 1): 2203.

https://doi.org/10.1182/blood-2023-179944

Published: 2023

Journal Articles

Comparative Analysis of Clinical Outcomes and Healthcare Resource Utilization (HRU) in Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Unfit for High-Intensity Chemotherapy Treated with Venetoclax (VEN) Vs Other Therapies: Results from the AML Real World Evidence (ARC) Initiative

Blood (2023) 142 (Supplement 1): 5173.

https://doi.org/10.1182/blood-2023-173283

Published: 2023

Journal Articles

A Matching-Adjusted Indirect Comparison of the Efficacy of Elranatamab and Teclistamab in Patients with Triple-Class Exposed/Refractory Multiple Myeloma

Isha Mol, Yannan Hu, Thomas W LeBlanc, Joseph C Cappelleri, Haitao Chu, Guido Nador, Didem Aydin, Alex Schepart, Patrick Hlavacek

Blood (2023) 142 (Supplement 1): 2015.

https://doi.org/10.1182/blood-2023-186409

Published: 2023

Journal Articles

Changing Care Journey for Patients with Multiple Myeloma in the United States

Darcy R Flora, Rachel Byrd, Daniel Platt, Patrick Hlavacek, Erinn Hoag Goldman, Joseph C Cappelleri, C Todd Kennedy, Thomas W LeBlanc

Blood (2023) 142 (Supplement 1): 7383.

https://doi.org/10.1182/blood-2023-179554

Published: 2023

Journal Articles

A Matching-Adjusted Indirect Comparison of the Efficacy of Elranatamab Versus Physician's Choice of Treatment in Patients with Triple-Class Exposed/Refractory Multiple Myeloma

Isha Mol, Yannan Hu, Thomas W LeBlanc, Joseph C Cappelleri, Haitao Chu, Guido Nador, Didem Aydin, Alex Schepart, Patrick Hlavacek

Blood (2023) 142 (Supplement 1): 6731.

https://doi.org/10.1182/blood-2023-185920

Published: 2023

NARROW

Disparities in CAR-T Therapy Access and Outcomes: Variation in Referral Patterns for CAR-T Therapy in Patients with Newly Diagnosed Malignancies at an Academic Center in North Carolina

The Impact of Multiple Myeloma on Care Partner Well-Being, Work Productivity, and Resource Use in the United States and Western Europe

Updated Results of a Matching-Adjusted Indirect Comparison of Elranatamab Versus Teclistamab in Patients with Triple-Class Exposed/Refractory Multiple Myeloma

An Indirect Comparison of Elranatamab's Progression-Free Survival, Duration of Response, and Overall Survival from MagnetisMM-3 Versus Real-World External Control Arms in Triple-Class Refractory Multiple Myeloma

Pre-Transplant Patient-Reported Outcomes Are Associated with Health Care Utilization and Transplant-Related Complications at One-Year Post-Transplant

Multi-Site Randomized Trial of a Collaborative Palliative and Oncology Care Model for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Receiving Non-Intensive Therapy

Treatment Experience of Patients with Acute Myeloid Leukemia in the Era of Novel Therapies: A Longitudinal Electronic Patient-Reported Outcomes Study

Perceptions of Treatment Tolerability and Its Relationship to Income in Patients with Hematologic Malignancy: Findings from the Cancer Experience Registry

Factors Associated with Early Quality of Life Response to Palliative Care during Hematopoietic Cell Transplantation

Experienced or Perceived Burdens and Associated Quality of Life Impacts of Anemia and Transfusion Dependence in Myelofibrosis: A Patient Self-Report Survey Analysis

Updated Results of a Matching-Adjusted Indirect Comparison of Elranatamab Versus Physician's Choice of Treatment in Patients with Triple-Class Exposed/Refractory Multiple Myeloma

Outcomes By Frailty in IC-Ineligible Newly Diagnosed AML - a Real-World Evidence Comparison By Treatment with Hypomethylating Agents + Ivosidenib or Venetoclax

Understanding Sociodemographic Barriers in Hematopoietic Stem Cell Transplantation Among Patients with Hematologic Malignancies: Insights from a North Carolina Cohort

A Comparison of Acute Myeloid Leukemia (AML) Regimens: Hypomethylating Agents Combined with Ivosidenib or Venetoclax in Newly Diagnosed Patients with IDH1 Mutations: A Real-World Evidence Study

Multi-Site Randomized Trial of Inpatient Palliative Care for Hospitalized Patients Undergoing Hematopoietic Stem Cell Transplantation

A Positive Psychology Intervention in Allogeneic Hematopoietic Stem Cell Transplantation Survivors (PATH) to Promote Well-Being: Randomized Controlled Feasibility and Preliminary Efficacy Trial

A Matching-Adjusted Indirect Comparison of the Efficacy of Elranatamab and Teclistamab in Patients with Triple-Class Exposed/Refractory Multiple Myeloma

Changing Care Journey for Patients with Multiple Myeloma in the United States

A Matching-Adjusted Indirect Comparison of the Efficacy of Elranatamab Versus Physician's Choice of Treatment in Patients with Triple-Class Exposed/Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only